Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANI Has Four-Pillar Growth Strategy Following Novitium Deal

As Company Sees Q4 Revenue Increase On The Back Of Generics Sales

Executive Summary

With a four-pillar growth strategy, ANI Pharma plans over 25 product launches in 2021 and 2022. With the recent acquisition of Novitium the company is also advancing three 505(b)(2) candidates in oncology and hypertension, after seeing a slight growth in overall revenues and generics sales in 2020. 

You may also be interested in...



ANI Pharmaceuticals Completes $210m Novitium Acquisition

ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.

ANI Prepares For Cortrophin Launch

US-based ANI Pharmaceuticals is looking to strengthen its leadership team and strategize a commercial approach for the launch of Cortrophin Gel, as it anticipates FDA approval by 29 October 2021. ANI reported a 2.4% increase in its generics business.

ANI Transforms With Novitium And Sandoz Deals

US generics player ANI Pharmaceutical is looking to file a supplemental new drug application of corticotropin gel with the FDA, with the company seeing the Cortrophin product as a “transformational opportunity.” The company also expects to close its acquisition of Novitium in the second half of 2021, anticipating over 25 product launches. 

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB150769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel